Health Canada approves Celltrion’s Omlyclo™ (CT-P39), the first and only omalizumab ...
Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer
Whether you want passive income or not, dividend-paying stocks tend to outperform their non-dividend-paying cousins.
来自MSN5 天
Celltrion's asthma treatment greenlit for Canadian release
Celltrion's asthma treatment Omlyclo, a biosimilar of Novartis's Xolair, has received Canadian approval for chronic urticaria, rhinosinusitis, and allergic asthma ...
Daily5 天
Vitamin D deficiency linked to severity of chronic rhinosinusitis with nasal polyposi ...
A new study published in the Ear, Nose and Throat Journal found that the severity of chronic rhinosinusitis with nasal ...
The 7 most common types of cough and how to treat each one – plus when you need to see a ...
IT’S that time of year where we’re greeted by a cacophony of coughs, sneezes and sniffles wherever we go. You might think a cough is a cough, but different conditions will produce a ...